Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of injectable TQB2102 in HER2-aberrant locally advanced or metastatic non-small cell lung cancer
CTR20242017Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2102 in non-small cell lung cancer (NSCLC), sponsored by Nanjing Shunxin Pharmaceutical. Started Aug 2024; status: active.
02
Drugs
TQB2102
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20242017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242017.